Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Xiaotian Zhang; Liang Han; Ziyu Li; Yingwei Xue; Yanong Wang; Zhiwei Zhou; Jiren Yu; Zhaode Bu; Lin Chen; Yian Du; Xinbao Wang; Aiwen Wu; Guoli Li; Xiangqian Su; Gang Xiao; Ming Cui; Dan Wu; Li Chen; Xiaojiang Wu; Yanbing Zhou; Lianhai Zhang; Chengxue Dang; Yulong He; Zhongtao Zhang; Yihong Sun; Yong Li; Huanqiu Chen; Yuxian Bai; Changsong Qi; Peiwu Yu; Guanbao Zhu; Jian Suo; Baoqing Jia; Leping Li; Ze-Ning Huang; Fei Li; Yingjiang Ye; Huimian Xu; Xin Wang; Yannan Yuan; E Jian‐Yu; Xiangji Ying; Chen Yao; Lin Shen; Jiafu Ji

doi:10.1016/s1470-2045(21)00297-7

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Xiaotian Zhang(Peking University), Liang Han(Tianjin Medical University Cancer Institute and Hospital), Ziyu Li(Peking University Cancer Hospital), Yingwei Xue(Harbin Medical University), Yanong Wang(Fudan University Shanghai Cancer Center), Zhiwei Zhou(Sun Yat-sen University), Jiren Yu(First Affiliated Hospital Zhejiang University), Zhaode Bu(Peking University), Lin Chen(Second Affiliated Hospital of Zhejiang University), Yian Du(Zhejiang Cancer Hospital), Xinbao Wang(Zhejiang Cancer Hospital), Aiwen Wu(Peking University), Guoli Li(Nanjing General Hospital of Nanjing Military Command), Xiangqian Su(Peking University), Gang Xiao(Beijing Hospital), Ming Cui(Peking University), Dan Wu(Second Affiliated Hospital of Zhejiang University), Li Chen(Chinese PLA General Hospital), Xiaojiang Wu(Peking University), Yanbing Zhou(Qingdao University), Lianhai Zhang(Peking University Cancer Hospital), Chengxue Dang(First Affiliated Hospital of Xi'an Jiaotong University), Yulong He(The First Affiliated Hospital, Sun Yat-sen University), Zhongtao Zhang(Beijing Friendship Hospital), Yihong Sun(Zhongshan Hospital), Yong Li(Hebei Medical University), Huanqiu Chen(Jiangsu Cancer Hospital), Yuxian Bai(Third Affiliated Hospital of Harbin Medical University), Changsong Qi(Peking University), Peiwu Yu(Army Medical University), Guanbao Zhu(Wenzhou Medical University), Jian Suo(Jilin University), Baoqing Jia(Chinese PLA General Hospital), Leping Li(Shandong Provincial Hospital), Ze-Ning Huang(Union Hospital), Fei Li(Capital Medical University), Yingjiang Ye(Peking University), Huimian Xu(First Hospital of China Medical University), Xin Wang(Zhejiang Cancer Hospital), Yannan Yuan(Peking University), E Jian‐Yu(Johns Hopkins University), Xiangji Ying(Peking University Cancer Hospital), Chen Yao(Peking University), Lin Shen(Peking University), Jiafu Ji(Peking University Cancer Hospital)

The Lancet Oncology

July 9, 2021

10.1016/s1470-2045(21)00297-7

Cited by 433

Abstract

Related Papers

No related papers found

Powered by citation graph analysis